Summary: In 43 nondiabetic men aged 45 to 55 with metabolic syndrome, six months of lifestyle-induced weight loss was associated with 642 differentially expressed genes in subcutaneous adipose tissue, with strongest enrichment in cholesterol-related pathways. A three-gene signature (SUMO3, PRKG2, ADAP2) reportedly predicted sustained loss of more than 10% of body weight with an AUC of 0.963, an exploratory finding requiring external validation.
PICO Summary
| Element | Detail |
|---|---|
| Population | 43 nonsmoking, nondiabetic men aged 45 to 55 years with metabolic syndrome; prospective, single-centre, two-arm randomised 6-month interventional trial (Germany). DEGs were validated in two separate cross-sectional cohorts. |
| Intervention | Lifestyle-induced weight loss (LIWL) over 6 months through dietary change and increased physical activity. |
| Comparison | Controlled trial design; transcriptional regulation in subcutaneous adipose tissue assessed before versus after LIWL, with cross-sectional comparison of individuals with and without obesity. |
| Outcome | 642 differentially expressed genes identified in subcutaneous adipose tissue after 6 months; strongest gene-enrichment association with cholesterol metabolic processes, correlated with serum HDL cholesterol, LDL cholesterol, and triglycerides. A 3-gene signature (SUMO3, PRKG2, ADAP2) was associated with loss of more than 10% of initial body weight maintained for at least 12 months, AUC 0.963 (95% CI 0.906 to 1.0). No formal clinical efficacy endpoint, p-values, or absolute risk measures were the basis of these exploratory transcriptomic analyses. |
Expert Commentary
This work is best read as a mechanistic and biomarker-discovery study rather than a test of clinical efficacy. Within a small single-centre randomised trial, transcriptomic profiling of subcutaneous adipose tissue identified 642 differentially expressed genes after six months of lifestyle-induced weight loss, with enrichment in cholesterol-handling pathways that aligned with serum lipid changes. The biological signal is coherent and is partly supported by validation in two independent cross-sectional cohorts. The reported three-gene predictive signature, however, should be interpreted with caution. An AUC of 0.963 derived in 43 participants, all middle-aged nondiabetic men, is implausibly high for a generalisable predictor and almost certainly reflects optimistic in-sample performance; without prospective external validation it cannot guide selection of who will sustain weight loss. The most weighable limitation is therefore the narrow, homogeneous population, which excludes women, people with diabetes, and other age groups, and constrains external validity. Can I use this with my patients? Not yet. The findings sharpen our understanding of how adipose tissue remodels with weight loss, but they do not provide a tool I would apply at the bedside to predict or modify outcomes. I would welcome a larger, sex-balanced, prospectively validated study before any clinical translation is considered. Funding and potential conflicts of interest should be checked in the full paper.
References
Zimmermann S, Roomp K, Meyer HJ, et al. Association of Lifestyle-Induced Weight Loss With Gene Expression in Subcutaneous Adipose Tissue in Metabolic Syndrome. J Diabetes. 2025;17(4):e70083. doi:10.1111/1753-0407.70083